IPCALAB · NSE
IPCA Laboratories Limited
₹2,009.6
+1.99% (+₹39.3)
Prev. close
₹1,970.3
Volume
5,27,501
Delivery %
68.6%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on IPCA Laboratories for intraday trading, recommending a buy at ₹1,988 with a target price of ₹2,127 and a stop…” | Sumeet BagadiaChoice Equity Broking | IPCA Laboratories | PENDING |
Fundamentals
About IPCA Laboratories Limited
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetes, diabetology, emollients/protectives, fever, gastroenterology, haematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, regenerative, respiratory, rheumatology, and urology. The company also exports its products to Europe, Africa, the Americas, rest of Asia, the Commonwealth of Independent States, and Australasia. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Pranay Premchand Godha
Headquarters
Mumbai
Employees
17,210
Website
ipca.comExchange
View on NSE ↗Key stats
Market cap
₹50,984.40 Cr
P/E ratio (TTM)
38.9
Dividend yield
0.30%
EPS (TTM)
₹51.62
Beta (1Y · daily vs NIFTY 50)
0.01
Beta (5Y · monthly vs NIFTY 50)
0.29
Shares float
13.93 Cr
EPS · quarter ended Jun 2026
₹15.84
Upcoming earnings
12 Nov 2026
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.6% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹5,419.99 Cr | ₹5,829.79 Cr | ₹6,244.32 Cr | ₹7,705.04 Cr | ₹8,939.59 Cr | ₹9,646.33 Cr | |
| EBITDA | ₹1,607.19 Cr | ₹1,375.83 Cr | ₹1,052.39 Cr | ₹1,338.18 Cr | ₹1,613.89 Cr | ₹2,066.58 Cr |
| ₹1,140.01 Cr | ₹884.08 Cr | ₹471.32 Cr | ₹547.35 Cr | ₹737.68 Cr | ₹1,141.12 Cr | |
| Diluted EPS | ₹45.06 | ₹34.85 | ₹18.58 | ₹21.57 | ₹29.08 | ₹44.98 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹6,066.00 Cr | ₹7,637.00 Cr | ₹8,623.00 Cr | ₹11,097.00 Cr | ₹11,744.00 Cr | ₹12,350.00 Cr | |
| — | ₹807.22 Cr | ₹1,481.27 Cr | ₹1,438.36 Cr | ₹1,362.74 Cr | ₹808.76 Cr | |
| Stockholders' equity | ₹4,701.00 Cr | ₹5,492.00 Cr | ₹5,842.00 Cr | ₹6,332.00 Cr | ₹6,948.00 Cr | ₹8,063.00 Cr |
Total debt, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,090.00 Cr | ₹856.00 Cr | ₹806.00 Cr | ₹945.00 Cr | ₹1,321.00 Cr | ₹1,142.00 Cr | |
| Investing cash flow | ₹-520.69 Cr | ₹-855.05 Cr | ₹-725.00 Cr | ₹-1,291.79 Cr | ₹-869.50 Cr | ₹-246.77 Cr |
| ₹-306.00 Cr | ₹427.00 Cr | ₹507.00 Cr | ₹-553.00 Cr | ₹-283.00 Cr | ₹-754.00 Cr | |
| Capital expenditure | ₹-362.00 Cr | ₹-479.00 Cr | ₹-494.00 Cr | ₹-411.00 Cr | ₹-776.00 Cr | ₹-656.00 Cr |
| End cash position | — | ₹990.93 Cr | ₹1,578.98 Cr | ₹755.79 Cr | ₹924.63 Cr | ₹1,066.30 Cr |
End cash position has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Dec 23(10Q) | Mar 24–Sep 24(3Q) | Dec 24–Jun 26(7Q) |
|---|---|---|---|
| Promoter | 46.29% | 46.30% | 44.72% |
| Public | 53.71% | 53.70% | 55.28% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| IPCA Laboratories Limited | ₹49,987.34 Cr | ₹2,009.6 | 38.1 | 6.20 | 14.2% | 0.10 | +8.0% | +49.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
25 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Pharma sector stocks today, September 15: Alembic Pharma jumps 1.58%, Strides Pharma up 0.93%; Divi’s Laboratories falls 1.21%
IPCA Laboratories shares climbed 0.75% to ₹1,984.25 in early trade on Tuesday, September 15. This gain occurred as the pharmaceutical sector experienced mixed trading, with some stocks rising while others, including Divi’s Laboratories and Cipla, declined. The overall healthcare index fell 0.33%.
Tata Capital Healthcare Fund to exit Linux Laboratories as ChrysCapital buys 20-25% stake
The Economic Times · 10 days ago